AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36811474 — intervention group
Group type: COMPARATOR
Intervention: 0% cellular chickpea powder (CCP) bread
Number of subjects: 20
Study 36811476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 109
Study 36811476 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 109
Study 36811520 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuranolone
Number of subjects: 0
Study 36811520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36811557 — intervention group
Group type: EXPERIMENTAL
Intervention: cBMA augmentation
Number of subjects: 91
Study 36811557 — intervention group
Group type: COMPARATOR
Intervention: aRCR alone (control)
Number of subjects: 91
Study 36811565 — intervention group
Group type: EXPERIMENTAL
Intervention: More proinflammatory diet (EDIP score +0.75)
Number of subjects: 1631
Study 36811565 — intervention group
Group type: COMPARATOR
Intervention: Median EDIP score (0)
Number of subjects: 1631
Study 36811566 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex lifestyle intervention (infographics and face-to-face group sessions)
Number of subjects: 132
Study 36811566 — intervention group
Group type: COMPARATOR
Intervention: Infographics only (Control)
Number of subjects: 132
Study 36811567 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic prolonged fasting (PF)
Number of subjects: 20
Study 36811567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive metabolites (spermidine, 1-methylnicotinamide, palmitoylethanolamide, oleoylethanolamide)
Number of subjects: 20
Study 36811568 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic intervention formula (IF) containing Limosilactobacillus fermentum CECT5716 and galacto-oligosaccharides
Number of subjects: 540
Study 36811568 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 540
Study 36811718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Number of subjects: 15
Study 36811773 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2% applied twice daily for 28 days
Number of subjects: 0
Study 36811812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg bid
Number of subjects: 402
Study 36811812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine (all doses)
Number of subjects: 402
Study 36811812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 36811822 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant osimertinib
Number of subjects: 0
Study 36811822 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance (placebo)
Number of subjects: 0
Study 36811831 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOLs
Number of subjects: 67
Study 36811831 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOF IOLs
Number of subjects: 67
Study 36811831 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 67
Study 36811846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 0.6% ophthalmic solution
Number of subjects: 228
Study 36811846 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen 0.025%
Number of subjects: 228
Study 36811861 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 100
Study 36811861 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (SA)
Number of subjects: 100
Study 36811901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 11005
Study 36811901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11005
Study 36811902 — intervention group
Group type: EXPERIMENTAL
Intervention: EIS (OPUS)
Number of subjects: 547
Study 36811902 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 547
Study 36811905 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered meetings with nurses
Number of subjects: 16
Study 36811937 — intervention group
Group type: EXPERIMENTAL
Intervention: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home), 10-week intervention
Number of subjects: 70
Study 36811937 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 70
Study 36811937 — intervention group
Group type: EXPERIMENTAL
Intervention: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home)
Number of subjects: 70
Study 36811949 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg subcutaneously every 4 weeks for 16 weeks
Number of subjects: 20
Study 36811949 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 20
Study 36811949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from NOVA trial)
Number of subjects: 20
Study 36811949 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (from NOVA trial)
Number of subjects: 20
Study 36811952 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Parenting App (SPA)
Number of subjects: 400
Study 36811952 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 400
Study 36811991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) 500 mg administered <48 hours before surgery
Number of subjects: 23
Study 36812121 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise program
Number of subjects: 161
Study 36812121 — intervention group
Group type: COMPARATOR
Intervention: Routine daily physical activity (control)
Number of subjects: 161
Study 36812248 — intervention group
Group type: EXPERIMENTAL
Intervention: PedaleoVR (virtual reality system for pedaling exercise)
Number of subjects: 38
Study 36812346 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 58
Study 36812382 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-to-care strategy with public health field services
Number of subjects: 1893
Study 36812382 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1893
Study 36812432 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound ablation
Number of subjects: 94
Study 36812432 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 94
Study 36812434 — intervention group
Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec gene therapy (AAV5 vector expressing Padua factor IX variant)
Number of subjects: 0
Study 36812434 — intervention group
Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec gene therapy
Number of subjects: 0
Study 36812434 — intervention group
Group type: COMPARATOR
Intervention: Factor IX prophylaxis (control)
Number of subjects: 0
Study 36812433 — intervention group
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec therapy (single infusion of 6×10^13 vg/kg)
Number of subjects: 134
Study 36812433 — intervention group
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec therapy
Number of subjects: 134
Study 36812441 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 36812571 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model derived on the European cohort
Number of subjects: 3933
Study 36812616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-derived daily activity
Number of subjects: 68
Study 36812616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-derived median heart rate
Number of subjects: 68
Study 36812616 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported symptom burden
Number of subjects: 68
Study 36812663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention for 10 weeks
Number of subjects: 190
Study 36812663 — intervention group
Group type: COMPARATOR
Intervention: Health Promotion (HP) intervention for 10 weeks
Number of subjects: 190
Study 36812723 — intervention group
Group type: EXPERIMENTAL
Intervention: AFD-specific treatment
Number of subjects: 7671
Study 36812723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphedema prevalence
Number of subjects: 7671
Study 36812723 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 7671
Study 36812723 — intervention group
Group type: COMPARATOR
Intervention: Classic phenotype
Number of subjects: 7671
Study 36812894 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrition protocol (early initiation of intralipids and faster advancement of glucose infusion rate)
Number of subjects: 90
Study 36812894 — intervention group
Group type: COMPARATOR
Intervention: Standard PN protocol
Number of subjects: 90
Study 36812938 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Symptoms (PTSS) measured using the Impact of Event Scale-Revised
Number of subjects: 386
Study 36812938 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with PTSS
Number of subjects: 386
Study 36812938 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life, sleep, and cognition
Number of subjects: 386
Study 36812938 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 386
Study 36812948 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF)
Number of subjects: 0
Study 36812948 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF)
Number of subjects: 0
Study 36812948 — intervention group
Group type: COMPARATOR
Intervention: sacubitril/valsartan
Number of subjects: 0
Study 36813015 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion (ROM) training started at 3 days postoperative
Number of subjects: 200
Study 36813015 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) started at 3 weeks postoperative
Number of subjects: 200
Study 36813015 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 200
Study 36813084 — intervention group
Group type: EXPERIMENTAL
Intervention: W-SUDs (relational agent)
Number of subjects: 400
Study 36813084 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control
Number of subjects: 400
Study 36813086 — intervention group
Group type: COMPARATOR
Intervention: Youth-centered education and counseling (standard of care)
Number of subjects: 880
Study 36813086 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic peer navigation (peer support via phone and automated monthly text messages)
Number of subjects: 880
Study 36813086 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity re-engagement interventions (for those with a lapse in engagement)
Number of subjects: 880
Study 36813177 — intervention group
Group type: EXPERIMENTAL
Intervention: DeepTOP tool for tumor segmentation and outcome prediction using MRI
Number of subjects: 99
Study 36813177 — intervention group
Group type: EXPERIMENTAL
Intervention: DeepTOP tool for predicting pathological complete response to chemo/radiotherapy
Number of subjects: 99
Study 36813284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted antibiotic stewardship intervention
Number of subjects: 1041
Study 36813284 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1041
Study 36813373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter AVR
Number of subjects: 1974
Study 36813373 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical AVR
Number of subjects: 1974
Study 36813373 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in stage of cardiac damage at 1 year after AVR
Number of subjects: 1974
Study 36813375 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-derived radial wall strain (RWS) analysis
Number of subjects: 751
Study 36813375 — intervention group
Group type: COMPARATOR
Intervention: Physiological evaluation (control group)
Number of subjects: 751
Study 36813380 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rhythm control of atrial fibrillation
Number of subjects: 0
Study 36813380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36813496 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP-25 gel (topical application on suction blister wounds)
Number of subjects: 24
Study 36813496 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (topical application on suction blister wounds)
Number of subjects: 24
Study 36813503 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide 320 µg two times a day for 14 days
Number of subjects: 98
Study 36813503 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 98
Study 36813502 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (gastrectomy, esophagectomy, pancreas resection or hepatectomy)
Number of subjects: 0
Study 36813504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 5 mg/g ear drops (Otalgan) one to two drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics)
Number of subjects: 300
Study 36813504 — intervention group
Group type: COMPARATOR
Intervention: Usual care (oral analgesics, with/without antibiotics)
Number of subjects: 300
Study 36813656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily
Number of subjects: 817
Study 36813747 — intervention group
Group type: EXPERIMENTAL
Intervention: SH-1028 200 mg once daily
Number of subjects: 20
Study 36813747 — intervention group
Group type: EXPERIMENTAL
Intervention: SH-1028 240 mg cohort
Number of subjects: 20
Study 36813747 — intervention group
Group type: EXPERIMENTAL
Intervention: SH-1028 300 mg cohort
Number of subjects: 20
Study 36813747 — intervention group
Group type: EXPERIMENTAL
Intervention: SH-1028
Number of subjects: 20
Study 36813798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predictive model based on age, Glasgow Coma Scale (GCS) at admission, and hydrocephalus caused by intraventricular hemorrhage (IVH)
Number of subjects: 692
Study 36813798 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 692
Study 36813798 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale (GCS) at admission
Number of subjects: 692
Study 36813798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocephalus caused by intraventricular hemorrhage (IVH)
Number of subjects: 692
Study 36813867 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant nab-paclitaxel + gemcitabine chemotherapy
Number of subjects: 146
Study 36813867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential nab-paclitaxel + gemcitabine chemotherapy
Number of subjects: 146
Study 36813886 — intervention group
Group type: EXPERIMENTAL
Intervention: Indotecan
Number of subjects: 41
Study 36813886 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dosing regimen of indotecan
Number of subjects: 41
Study 36813902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Hypertension (cHTN)
Number of subjects: 0
Study 36813902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive Disorders of Pregnancy (HDP)
Number of subjects: 0
Study 36813902 — intervention group
Group type: COMPARATOR
Intervention: No Hypertension (HTN)
Number of subjects: 0
Study 36813985 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program
Number of subjects: 60
Study 36813985 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 60
Study 36814010 — intervention group
Group type: EXPERIMENTAL
Intervention: PedsQL scores
Number of subjects: 1735
Study 36814010 — intervention group
Group type: EXPERIMENTAL
Intervention: OLS estimation method
Number of subjects: 1735
Study 36814010 — intervention group
Group type: EXPERIMENTAL
Intervention: CYPHP mapping algorithms
Number of subjects: 1735
Study 36814062 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 2568
Study 36814062 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 2568
Study 36814062 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2568
Study 36814062 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib/adalimumab
Number of subjects: 2568
Study 36814182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 19112
Study 36814182 — intervention group
Group type: COMPARATOR
Intervention: Failed fibrinolysis
Number of subjects: 19112
Study 36814185 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized screening interval based on prior f-Hb concentration (1, 2 or 3 years)
Number of subjects: 20000
Study 36814185 — intervention group
Group type: COMPARATOR
Intervention: Current practice screening interval (2 years)
Number of subjects: 20000
Study 36814185 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized screening
Number of subjects: 20000
Study 36814185 — intervention group
Group type: COMPARATOR
Intervention: Uniform screening
Number of subjects: 20000
Study 36814222 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib 160 mg daily on days 1 to 21 of each 28-day cycle (INTEGRATE IIa)
Number of subjects: 0
Study 36814222 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib 90 mg days 1 to 21 in combination with intravenous nivolumab 240 mg days 1 and 15 each 28-day cycle (REGONIVO) (INTEGRATE IIb)
Number of subjects: 0
Study 36814222 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (control) (INTEGRATE IIb)
Number of subjects: 0
Study 36814246 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies (13 EMA-approved drugs)
Number of subjects: 0
Study 36814280 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota diversity (Shannon index) in ICU patients
Number of subjects: 123
Study 36814280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysbiosis index in ICU patients
Number of subjects: 123
Study 36814280 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota alterations
Number of subjects: 123
Study 36814310 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Well
Number of subjects: 40
Study 36814310 — intervention group
Group type: COMPARATOR
Intervention: RPM (with in-house modification)
Number of subjects: 40
Study 36814313 — intervention group
Group type: EXPERIMENTAL
Intervention: MoviS Training (12 weeks of aerobic exercise training, 2 days/week supervised and 1 day/week unsupervised, 40-70% of heart rate reserve, 20-60 min duration)
Number of subjects: 172
Study 36814313 — intervention group
Group type: EXPERIMENTAL
Intervention: MoviS Training (12 weeks of aerobic exercise training)
Number of subjects: 172
Study 36814313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle recommendations and MoviS Training
Number of subjects: 172
Study 36814313 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle recommendations
Number of subjects: 172
Study 36814438 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum high-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 183
Study 36814438 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers (including hs-CRP, TNF-α, IL-1β, IL-6, IL-8, MCP-1)
Number of subjects: 183
Study 36814526 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental thickness measurement
Number of subjects: 40
Study 36814526 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold placental thickness of 58mm
Number of subjects: 40
Study 36814526 — intervention group
Group type: EXPERIMENTAL
Intervention: History of more than three cesarean sections
Number of subjects: 40
Study 36814594 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive for vaccination
Number of subjects: 406
Study 36814594 — intervention group
Group type: COMPARATOR
Intervention: Cost for vaccination
Number of subjects: 406
Study 36814594 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-monetary incentives
Number of subjects: 406
Study 36814594 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 406
Study 36814898 — intervention group
Group type: EXPERIMENTAL
Intervention: Serclutamab talirine (Ser-T) monotherapy at doses up to 50 μg/kg, followed by 25 μg/kg Q4W
Number of subjects: 62
Study 36814898 — intervention group
Group type: EXPERIMENTAL
Intervention: Serclutamab talirine (Ser-T) at recommended phase II dose (RP2D)
Number of subjects: 62
Study 36815187 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 0
Study 36815187 — intervention group
Group type: COMPARATOR
Intervention: Placebo with therapy
Number of subjects: 0
Study 36815261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health Narrative Community-Based Group Therapy (NCGT)
Number of subjects: 0
Study 36815261 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36815322 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP therapy (weekly rifapentine plus isoniazid)
Number of subjects: 1002
Study 36815378 — intervention group
Group type: EXPERIMENTAL
Intervention: NUP98-NSD1
Number of subjects: 2235
Study 36815378 — intervention group
Group type: EXPERIMENTAL
Intervention: NUP98-KDM5A
Number of subjects: 2235
Study 36815378 — intervention group
Group type: EXPERIMENTAL
Intervention: NUP98-X
Number of subjects: 2235
Study 36815378 — intervention group
Group type: EXPERIMENTAL
Intervention: NUP98 fusions
Number of subjects: 2235
Study 36815464 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led health coaching intervention with 4 additional group education sessions and individualized health coaching over a 6-month period
Number of subjects: 303
Study 36815464 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 303
Study 36815750 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 6
Study 36816341 — intervention group
Group type: COMPARATOR
Intervention: Polypill therapy (combination of ≥2 blood pressure medications and a statin with or without aspirin)
Number of subjects: 2880
Study 36816341 — intervention group
Group type: COMPARATOR
Intervention: High-risk primary prevention (age ≥40 years, hypertension, or predicted 10-year ASCVD risk ≥7.5%)
Number of subjects: 2880
Study 36816341 — intervention group
Group type: COMPARATOR
Intervention: Secondary prevention (history of stroke or myocardial infarction)
Number of subjects: 2880
Study 36816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg, three times daily for 12 months)
Number of subjects: 128
Study 36816343 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 128